Vir Biotechnology Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. Stockholders elected Jeffrey S. Hatfield and Saira Ramasastry as Class III directors. The advisory vote on executive compensation was approved. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-028356), on May 29, 2025, and is solely responsible for the information contained therein.
Comments